Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Expected to Post Quarterly Sales of $430,000.00

Equities research analysts expect that Inovio Pharmaceuticals, Inc. (NASDAQ:INOGet Rating) will report sales of $430,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The highest sales estimate is $850,000.00 and the lowest is $180,000.00. Inovio Pharmaceuticals reported sales of $270,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 59.3%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Inovio Pharmaceuticals will report full year sales of $1.51 million for the current fiscal year, with estimates ranging from $830,000.00 to $2.75 million. For the next fiscal year, analysts anticipate that the business will report sales of $43.67 million, with estimates ranging from $750,000.00 to $129.25 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INOGet Rating) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.66 million. Inovio Pharmaceuticals had a negative net margin of 20,479.29% and a negative return on equity of 76.48%. The firm’s revenue was down 46.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) EPS.

Several equities analysts have recently issued reports on INO shares. StockNews.com started coverage on Inovio Pharmaceuticals in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Wednesday, March 2nd. Oppenheimer cut Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 11th. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. Finally, Cantor Fitzgerald decreased their target price on Inovio Pharmaceuticals from $6.00 to $3.00 in a research report on Wednesday, May 11th. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.75.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP boosted its position in Inovio Pharmaceuticals by 10.0% during the first quarter. Quantbot Technologies LP now owns 57,000 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 5,200 shares during the last quarter. State Street Corp lifted its position in shares of Inovio Pharmaceuticals by 74.9% in the first quarter. State Street Corp now owns 23,267,928 shares of the biopharmaceutical company’s stock worth $83,532,000 after buying an additional 9,967,498 shares during the last quarter. Invesco Ltd. lifted its position in shares of Inovio Pharmaceuticals by 173.0% in the first quarter. Invesco Ltd. now owns 218,103 shares of the biopharmaceutical company’s stock worth $783,000 after buying an additional 138,226 shares during the last quarter. Smith Anglin Financial LLC acquired a new stake in shares of Inovio Pharmaceuticals in the first quarter worth about $36,000. Finally, UBS Group AG lifted its position in shares of Inovio Pharmaceuticals by 99.3% in the first quarter. UBS Group AG now owns 1,640,012 shares of the biopharmaceutical company’s stock worth $5,888,000 after buying an additional 817,297 shares during the last quarter. 43.28% of the stock is owned by hedge funds and other institutional investors.

Shares of Inovio Pharmaceuticals stock opened at $1.88 on Friday. The business’s fifty day moving average price is $3.04 and its two-hundred day moving average price is $4.36. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.74 and a quick ratio of 6.74. The company has a market capitalization of $430.60 million, a P/E ratio of -1.22 and a beta of 0.80. Inovio Pharmaceuticals has a 1-year low of $1.60 and a 1-year high of $10.33.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Recommended Stories

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.